Effects of age and gender on in vitro properties of human liver microsomal monooxygenases

Clinical Pharmacology and Therapeutics
D L SchmuckerP Kremers

Abstract

Aging in humans is associated with marked declines in the disposition of numerous drugs and other xenobiotics that require hepatic biotransformation before elimination. Considerable pharmacokinetic evidence in humans, coupled with data on in vitro liver microsomal monooxygenase functions generated in inbred male rodent models, has implicated impaired liver phase I drug metabolism (i.e., diminished efficacy of microsomal monooxygenases) in reduced drug clearance in the elderly. This study (1) assessed the in vitro activities and amounts of liver microsomal monooxygenases as a function of donor age and gender in healthy humans and (2) provides the most extensive and comprehensive data to date demonstrating the absence of significant age- and gender-dependent differences in the activities and contents of human liver monooxygenases.

Citations

Jul 1, 1992·The Annals of Pharmacotherapy·M Gibaldi
Jul 1, 1992·Biopharmaceutics & Drug Disposition·K Woodhouse
Oct 1, 1994·Journal of the American Geriatrics Society·K M TornatoreP J Davis
Feb 26, 2000·Journal of Internal Medicine·J Grimley Evans
Jan 22, 2003·Alimentary Pharmacology & Therapeutics·R CiccocioppoA Gasbarrini
Apr 20, 2004·British Journal of Clinical Pharmacology·M T Kinirons, M S O'Mahony
May 21, 2005·Drugs & Aging·Louis MerleJean-Pierre Charmes
Mar 18, 2006·British Journal of Clinical Pharmacology·Sarah M RobertsonScott R Penzak
Jan 2, 2009·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Chad M ThompsonKannan Krishnan
Sep 19, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xiaochao MaFrank J Gonzalez
Nov 1, 1992·Xenobiotica; the Fate of Foreign Compounds in Biological Systems· SugiyantoA J Ryan
May 23, 1998·Annual Review of Pharmacology and Toxicology·K E Thummel, G R Wilkinson
Mar 28, 1998·British Journal of Clinical Pharmacology·M F FrommU Klotz
Jun 26, 1999·British Journal of Clinical Pharmacology·D J CarlileJ B Houston
Jan 27, 2004·The Journal of Pharmacology and Experimental Therapeutics·Jill S WarringtonLisa L von Moltke
Sep 2, 2008·Journal of Clinical Pharmacology·David J Greenblatt, Lisa L von Moltke
Mar 25, 2008·Therapeutics and Clinical Risk Management·Sarah N HilmerDavid G Le Couteur
Jun 12, 2009·Drug Metabolism Reviews·Ulrich Klotz
Mar 18, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Louise SivertssonEtienne P A Neve
Jun 5, 2008·Expert Opinion on Drug Metabolism & Toxicology·Marissa J ScandlynRhonda J Rosengren
Aug 11, 2020·Clinical Pharmacology and Therapeutics·Felix StaderCatia Marzolini
Oct 1, 1995·British Journal of Clinical Pharmacology·S K GuptaJ A Longstreth
Jan 1, 1994·International Archives of Occupational and Environmental Health·J G Van RooijF J Jongeneelen
Oct 1, 1991·British Journal of Clinical Pharmacology·B T VeeringJ Spierdijk
Dec 23, 1998·Critical Reviews in Toxicology·A Löf, G Johanson
Sep 13, 2003·British Journal of Clinical Pharmacology·Z E WilsonG T Tucker
Nov 25, 2003·The Journal of Pharmacology and Experimental Therapeutics·Kiran C PatkiDavid J Greenblatt
Jun 12, 2004·Clinical and Experimental Pharmacology & Physiology·Céline Bertrand-ThiebaultSophie Visvikis
Mar 1, 2006·Pharmaceutical Research·Nancy HakoozJ Brian Houston
Oct 23, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jill S WarringtonDavid J Greenblatt
Oct 25, 2002·Journal of Women's Health & Gender-based Medicine·Marietta Anthony, Mary J Berg
Sep 14, 2011·Current Gerontology and Geriatrics Research·Douglas L Schmucker, Henry Sanchez
Aug 20, 2004·Journal of Clinical Pharmacology·Kathleen M TornatoreRocco C Venuto
Jun 1, 2004·Pharmacological Reviews·Allan J McLean, David G Le Couteur
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Monica GandhiTerrence F Blaschke
Nov 18, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Koichi Ueno, Hiromi Sato
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·J H Lin, A Y Lu
Nov 18, 2005·The Journal of Pharmacology and Experimental Therapeutics·Connie CheungFrank J Gonzalez

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.